FYERS
Home
/
Stocks
/
Profit Loss
/
Dr. Reddy's Laboratories Profit & Loss

Dr. Reddy's Laboratories Profit & Loss

Consolidated
Standalone
Quarterly
Yearly
₹
%
Name
Net Revenue
Other Income
Total Revenue
Total Expenditure
Operating Profit
Interest Expense
PBT
Net Profit
Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023Jun 2023Mar 2023Dec 2022Sep 2022Jun 2022Mar 2022Dec 2021Sep 2021Jun 2021Mar 2021Dec 2020Sep 2020Jun 2020Mar 2020Dec 2019Sep 2019Jun 2019Mar 2019Dec 2018Sep 2018Jun 2018Mar 2018Dec 2017Sep 2017Jun 2017Mar 2017Dec 2016Sep 2016Jun 2016Mar 2016Dec 2015Sep 2015Jun 2015Mar 2015Dec 2014Sep 2014Jun 2014Mar 2014Dec 2013Sep 2013Jun 2013Mar 2013Dec 2012Sep 2012Jun 2012Mar 2012Dec 2011Sep 2011Jun 2011Mar 2011Dec 2010Sep 2010Jun 2010Mar 2010Dec 2009Sep 2009Jun 2009Mar 2009Dec 2008Sep 2008Jun 2008Mar 2008Dec 2007Sep 2007Jun 2007Mar 2007Dec 2006Sep 2006Jun 2006Dec 2005Sep 2005Jun 2005
₹8100 Cr₹7546 Cr₹8753 Cr₹8828 Cr₹8572 Cr₹8528 Cr₹8381 Cr₹8038 Cr₹7696 Cr₹7114 Cr₹7237 Cr₹6903 Cr₹6758 Cr₹6315 Cr₹6790 Cr₹6332 Cr₹5233 Cr₹5475 Cr₹5338 Cr₹5787 Cr₹4945 Cr₹4768 Cr₹4942 Cr₹4911 Cr₹4427 Cr₹4449 Cr₹4397 Cr₹4813 Cr₹3858 Cr₹4030 Cr₹3865 Cr₹3818 Cr₹3737 Cr₹3554 Cr₹3834 Cr₹3560 Cr₹3333 Cr₹3612 Cr₹3723 Cr₹3616 Cr₹3245 Cr₹3795 Cr₹3968 Cr₹3989 Cr₹3758 Cr₹3870 Cr₹3843 Cr₹3588 Cr₹3518 Cr₹3481 Cr₹3534 Cr₹3357 Cr₹2845 Cr₹3340 Cr₹2865 Cr₹2881 Cr₹2541 Cr₹2658 Cr₹2769 Cr₹2268 Cr₹1978 Cr₹2017 Cr₹1899 Cr₹1870 Cr₹1683 Cr₹1656 Cr₹1730 Cr₹1858 Cr₹1821 Cr₹1935 Cr₹1846 Cr₹1620 Cr₹1499 Cr₹1261 Cr₹1240 Cr₹1249 Cr₹1186 Cr₹1738 Cr₹1495 Cr₹1944 Cr₹1349 Cr₹558 Cr₹564 Cr₹540 Cr
₹355 Cr₹475 Cr₹269 Cr₹324 Cr₹290 Cr₹522 Cr₹150 Cr₹308 Cr₹187 Cr₹198 Cr₹216 Cr₹315 Cr₹174 Cr₹139 Cr₹59 Cr₹41 Cr₹854 Cr₹122 Cr₹56 Cr₹206 Cr₹108 Cr₹83 Cr₹71 Cr₹51 Cr₹87 Cr₹74 Cr₹67 Cr₹54 Cr₹430 Cr₹83 Cr₹102 Cr₹128 Cr₹50 Cr₹45 Cr₹43 Cr₹32 Cr₹38 Cr₹21 Cr₹40 Cr₹44 Cr₹67 Cr₹85 Cr₹12 Cr₹32 Cr₹34 Cr₹13 Cr₹135 Cr₹69 Cr₹67 Cr₹39 Cr₹19 Cr₹93 Cr₹38 Cr₹203 Cr₹23 Cr₹77 Cr₹22 Cr₹28 Cr₹34 Cr₹22 Cr₹19 Cr₹51 Cr₹20 Cr₹22 Cr₹19 Cr-₹16 Cr₹17 Cr₹29 Cr₹19 Cr₹32 Cr₹9 Cr₹9 Cr₹49 Cr₹79 Cr₹26 Cr₹71 Cr₹64 Cr₹26 Cr₹27 Cr₹39 Cr₹25 Cr₹63 Cr₹21 Cr₹24 Cr
₹8455 Cr₹8022 Cr₹9022 Cr₹9152 Cr₹8862 Cr₹9051 Cr₹8531 Cr₹8346 Cr₹7883 Cr₹7311 Cr₹7453 Cr₹7218 Cr₹6932 Cr₹6454 Cr₹6849 Cr₹6373 Cr₹6087 Cr₹5597 Cr₹5394 Cr₹5992 Cr₹5053 Cr₹4851 Cr₹5012 Cr₹4962 Cr₹4514 Cr₹4523 Cr₹4464 Cr₹4867 Cr₹4288 Cr₹4113 Cr₹3967 Cr₹3946 Cr₹3787 Cr₹3599 Cr₹3877 Cr₹3591 Cr₹3371 Cr₹3632 Cr₹3764 Cr₹3660 Cr₹3312 Cr₹3880 Cr₹3980 Cr₹4021 Cr₹3792 Cr₹3883 Cr₹3979 Cr₹3656 Cr₹3584 Cr₹3520 Cr₹3553 Cr₹3450 Cr₹2882 Cr₹3543 Cr₹2888 Cr₹2958 Cr₹2562 Cr₹2686 Cr₹2803 Cr₹2289 Cr₹1997 Cr₹2068 Cr₹1918 Cr₹1892 Cr₹1702 Cr₹1639 Cr₹1747 Cr₹1887 Cr₹1839 Cr₹1968 Cr₹1855 Cr₹1630 Cr₹1548 Cr₹1340 Cr₹1266 Cr₹1320 Cr₹1250 Cr₹1764 Cr₹1521 Cr₹1983 Cr₹1374 Cr₹621 Cr₹585 Cr₹564 Cr
₹7777 Cr₹7721 Cr₹7387 Cr₹7323 Cr₹6875 Cr₹6985 Cr₹6580 Cr₹6359 Cr₹5947 Cr₹5650 Cr₹5587 Cr₹5270 Cr₹5049 Cr₹5097 Cr₹5175 Cr₹4742 Cr₹4594 Cr₹5317 Cr₹4417 Cr₹4721 Cr₹4495 Cr₹4024 Cr₹4714 Cr₹4071 Cr₹3598 Cr₹3774 Cr₹4973 Cr₹4062 Cr₹3406 Cr₹3498 Cr₹3350 Cr₹3337 Cr₹3246 Cr₹3267 Cr₹3313 Cr₹3161 Cr₹3269 Cr₹3276 Cr₹3125 Cr₹3252 Cr₹3098 Cr₹3590 Cr₹3222 Cr₹3095 Cr₹2999 Cr₹3271 Cr₹3155 Cr₹2968 Cr₹2889 Cr₹2918 Cr₹2687 Cr₹2685 Cr₹2465 Cr₹2760 Cr₹2436 Cr₹2396 Cr₹2171 Cr₹2261 Cr₹2031 Cr₹1915 Cr₹1718 Cr₹1684 Cr₹1625 Cr₹1570 Cr₹1439 Cr₹1451 Cr₹2341 Cr₹1598 Cr₹1490 Cr₹1573 Cr₹1623 Cr₹1499 Cr₹1401 Cr₹1185 Cr₹1144 Cr₹1175 Cr₹1031 Cr₹1213 Cr₹1296 Cr₹1558 Cr₹1182 Cr₹526 Cr₹486 Cr₹510 Cr
₹1215 Cr₹858 Cr₹2156 Cr₹2334 Cr₹2464 Cr₹2520 Cr₹2423 Cr₹2384 Cr₹2317 Cr₹2029 Cr₹2239 Cr₹2323 Cr₹2236 Cr₹1672 Cr₹1997 Cr₹1940 Cr₹1795 Cr₹573 Cr₹1272 Cr₹1565 Cr₹842 Cr₹1136 Cr₹610 Cr₹1207 Cr₹1208 Cr₹1023 Cr-₹221 Cr₹1118 Cr₹1172 Cr₹902 Cr₹907 Cr₹888 Cr₹819 Cr₹609 Cr₹836 Cr₹701 Cr₹361 Cr₹611 Cr₹905 Cr₹671 Cr₹457 Cr₹567 Cr₹758 Cr₹926 Cr₹793 Cr₹612 Cr₹824 Cr₹689 Cr₹696 Cr₹602 Cr₹866 Cr₹765 Cr₹417 Cr₹782 Cr₹453 Cr₹561 Cr₹392 Cr₹566 Cr₹903 Cr₹501 Cr₹402 Cr₹490 Cr₹400 Cr₹427 Cr₹360 Cr₹287 Cr₹370 Cr₹389 Cr₹453 Cr₹528 Cr₹355 Cr₹253 Cr₹265 Cr₹267 Cr₹215 Cr₹248 Cr₹313 Cr₹670 Cr₹318 Cr₹507 Cr₹277 Cr₹132 Cr₹134 Cr₹88 Cr
₹126 Cr₹106 Cr₹94 Cr₹91 Cr₹83 Cr₹66 Cr₹82 Cr₹76 Cr₹60 Cr₹59 Cr₹39 Cr₹35 Cr₹37 Cr₹35 Cr₹42 Cr₹31 Cr₹35 Cr₹32 Cr₹22 Cr₹23 Cr₹19 Cr₹30 Cr₹19 Cr₹25 Cr₹23 Cr₹23 Cr₹15 Cr₹30 Cr₹30 Cr₹25 Cr₹24 Cr₹21 Cr₹20 Cr₹18 Cr₹17 Cr₹22 Cr₹22 Cr₹20 Cr₹16 Cr₹13 Cr₹15 Cr₹17 Cr₹6 Cr₹22 Cr₹0₹23 Cr₹0₹0₹0₹0₹0₹0₹7 Cr₹0₹10 Cr₹0₹21 Cr₹0₹0₹5 Cr₹5 Cr-₹7 Cr₹5 Cr₹3 Cr₹18 Cr₹4 Cr₹5 Cr₹7 Cr₹12 Cr₹21 Cr₹28 Cr₹26 Cr₹23 Cr₹27 Cr₹21 Cr₹14 Cr₹34 Cr₹14 Cr₹52 Cr₹47 Cr₹39 Cr₹5 Cr₹5 Cr₹4 Cr
₹553 Cr₹195 Cr₹1541 Cr₹1739 Cr₹1905 Cr₹2000 Cr₹1870 Cr₹1911 Cr₹1877 Cr₹1602 Cr₹1826 Cr₹1913 Cr₹1846 Cr₹1322 Cr₹1632 Cr₹1600 Cr₹1459 Cr₹248 Cr₹956 Cr₹1248 Cr₹539 Cr₹797 Cr₹280 Cr₹866 Cr₹893 Cr₹726 Cr-₹524 Cr₹774 Cr₹853 Cr₹591 Cr₹593 Cr₹588 Cr₹521 Cr₹314 Cr₹547 Cr₹409 Cr₹81 Cr₹337 Cr₹622 Cr₹396 Cr₹199 Cr₹273 Cr₹752 Cr₹904 Cr₹793 Cr₹589 Cr₹824 Cr₹689 Cr₹696 Cr₹602 Cr₹866 Cr₹765 Cr₹410 Cr₹782 Cr₹443 Cr₹561 Cr₹371 Cr₹425 Cr₹772 Cr₹370 Cr₹274 Cr₹392 Cr₹288 Cr₹319 Cr₹245 Cr₹185 Cr-₹600 Cr₹283 Cr₹337 Cr-₹1089 Cr₹204 Cr₹104 Cr₹124 Cr₹127 Cr₹101 Cr₹131 Cr₹185 Cr₹537 Cr₹173 Cr₹377 Cr₹153 Cr₹90 Cr₹94 Cr₹50 Cr
₹435 Cr₹217 Cr₹1187 Cr₹1331 Cr₹1410 Cr₹1581 Cr₹1400 Cr₹1336 Cr₹1387 Cr₹1306 Cr₹1378 Cr₹1478 Cr₹1401 Cr₹953 Cr₹1238 Cr₹1100 Cr₹1180 Cr₹87 Cr₹691 Cr₹971 Cr₹364 Cr₹539 Cr₹13 Cr₹765 Cr₹587 Cr₹771 Cr-₹556 Cr₹1095 Cr₹660 Cr₹440 Cr₹491 Cr₹507 Cr₹468 Cr₹265 Cr₹294 Cr₹296 Cr₹57 Cr₹327 Cr₹483 Cr₹300 Cr₹146 Cr₹117 Cr₹573 Cr₹716 Cr₹621 Cr₹514 Cr₹570 Cr₹569 Cr₹545 Cr₹477 Cr₹614 Cr₹686 Cr₹357 Cr₹568 Cr₹360 Cr₹405 Cr₹334 Cr₹342 Cr₹510 Cr₹306 Cr₹262 Cr₹335 Cr₹273 Cr₹287 Cr₹209 Cr₹106 Cr-₹522 Cr₹240 Cr₹239 Cr-₹1255 Cr₹159 Cr₹87 Cr₹92 Cr₹78 Cr₹62 Cr₹110 Cr₹187 Cr₹439 Cr₹106 Cr₹292 Cr₹129 Cr₹64 Cr₹91 Cr₹31 Cr

Share Price Live Stats

Open (₹)1,157.00
Volume (₹)2.99 L
High (₹)1,166.80
Upper Circuit1,270.50
Low (₹)1,157.00
Lower Circuit1,039.50
Prev Close1,155.00
52W High (₹)1,414.90
Price1,161.90
52W Low (₹)1,101.00

Share Market Cap & Key Ratios Overview

M.Cap (₹)96405.50 Cr
Div. Yield (%)0.69
PE Ratio29.92
Debt to Equity0.20
Price to Book2.78
Book Value452.01
EPS (TTM)38.60
Face Value1.00
ROE (%)11.69

Stock Analysis (SWOT)

StrengthsWeaknessesOpportunitiesThreats
1. Premium insight available after login
2. Sign in to view full SWOT analysis
3. Unlock strengths, weaknesses, opportunities & threats
Sign in to view
Open a free Demat account in minutes to start investing and screening .
LoginSign Up

QVT

Quality
0/100-
Valuation
0/100-
Technical
0/100-
Sign in to view
Open a free Demat account in minutes to start investing and screening .
LoginSign Up

Peer Stocks

1 week
1 month
1 year
Name
SUNPHARMANSE
DIVISLABNSE
TORNTPHARMNSE
ZYDUSLIFENSE
CIPLANSE
LAURUSLABSNSE
LUPINNSE
MANKINDNSE
DRREDDYNSE
AUROPHARMANSE
LTP
1W Low
1W High
Market cap (₹)
1902.7-17.3 (-0.90%)
1900.10
1984.80
4,56,833Cr
9181.5-57.5 (-0.62%)
9087
9467
2,45,426Cr
4861-189 (-3.74%)
4857
5066
1,87,320Cr
1134.4-56.6 (-4.75%)
1125.10
1187
1,13,217Cr
1380.5-43 (-3.02%)
1376.70
1426.10
1,12,212Cr
1853.7-84.8 (-4.37%)
1811.70
1949
1,01,155Cr
2123.7-47.8 (-2.20%)
2118.10
2192
97,626Cr
2336.1-46.8 (-1.96%)
2335
2419.20
96,859Cr
1161.9-16.1 (-1.37%)
1154.40
1179.90
96,406Cr
1659+13.7 (0.83%)
1622.60
1717
93,614Cr

Key Highlights of Dr. Reddy's Laboratories Ltd’s P&L

In 2026-03-31, Dr. Reddy's Laboratories Ltd reported total revenue of ₹35058.6Cr, compared with ₹33741.2Cr in 2025-03-31, reflecting Dr. Reddy's Laboratories Ltd turnover.

Depreciation was ₹2058.8Cr and finance costs were ₹373.8Cr in 2026-03-31

Profit Before Tax (PBT) has been ₹5392.7Cr in 2026-03-31 as compared to ₹7679.5Cr in 2025-03-31.

Net Profit (PAT) was ₹4196Cr in 2026-03-31 compared with ₹5655.1Cr in 2025-03-31.

Earnings per share (EPS) were ₹50.25 in 2026-03-31, compared with ₹67.81 in 2025-03-31.